Alternatives to France – Blood-testing reagents – Fourniture de réactifs et consommables pour la réalisation d’analyses de gazométrie avec mise à disposition

France – Laboratory reagents – 051_2026_AO_Lecteurs glycémie_cétonémie

France – Functional support – SALLE HYPOXIQUE DE REEDUCATION

France – Imaging equipment for medical, dental and veterinary use – Fourniture, livraison et mise en service de scanners intraoraux sans fil pour les membres des Hôpitaux du Hainaut-Cambrésis

France – Dental consumables – Fourniture de matériels et consommables pour l’enseignement et les travaux pratiques de l’Ecole de Médecine Dentaire de Marseille

France – Pharmaceutical products – Accord-cadre à bons de commande Fourniture de vaccins et de produits pharmaceutiques pour la collectivité de Saint-Martin.

France – Catheters – Fourniture de dispositifs médicaux de chirurgie cardiaque, assistance cardiaque, chirurgie vasculaire, neuroradiologie et cardiologie interventionnelle.

France – Ambulance services – GROUPEMENT DE COMMANDE : MARCHE DE TRANSPORTS SANITAIRES TERRESTRES EN CONTINUITE DES SECOURS SUR PISTES SUR LES DOMAINES SKIABLES D'AUSSOIS-SARDIERES, LA NORMA ET VALFREJUS

France – Toilet paper, handkerchiefs, hand towels and serviettes – Fourniture de produits d'entretien pour les services du CD64, du SDIS64, de la MDPH64 et 27 Collèges publics du Département des Pyrénées-Atlantiques

Expected Impact: The action under this topic is expected to achieve the following impacts: Faster and more informed decision-making through the use of an AI-driven NAM (AI Foundation Toxicology Model) and increased efficiency through rapid processing of vast amounts of data [1] . Increased consistency and standardisation in a NAM-based approach, specifically an AI model, used by industry in the efficient development, testing and production of safe and effective innovative health technologies, improving industrial competitiveness. Regulatory adoption of a NAM-enabled second species waiver model (AI Foundation Toxicology Model) and weight-of-evidence framework, in line with recommendations and more consistent global decision-making on waiving second species testing. Reduction in animal use, accelerated timelines and lower costs, enhancing the competitiveness of the European health industry through economical and ethical benefits. Improved public health as patients will benefit from safe and effective medicines developed faster using validated NAMs. The action is expected to contribute to the EU Directive (2010/63/EU) [2] on the protection of animals used for scientific purposes and…

Expected Outcome: Successful proposals will contribute to the implementation of the EU initiative on Biotechnology and Biomanufacturing and the EU Life Sciences Strategy as well as the updated EU Bioeconomy Strategy, the upcoming EU Biotechnology Act and EU Circular Economy Act. Projects’ results are expected to contribute to the following expected outcomes: Full industrial scale biorefinery and related value chain(s) for the production of nutritional food ingredients. Resilience and strategic autonomy of EU food sectors via diversification of nutritional food ingredient sources. Increased environmental sustainability of food sectors (e.g. addressing issues like land use, water use, energy consumption, nitrogen cycle, other nutrients, etc.). Improved consumers awareness and acceptance of nutritional food ingredients from alternative sources, contributing to sustainable healthy diets. Scope: Human nutrition is a key area where the bio-based industries can play an important role in addressing the present societal and climate challenges. Considerable attention is given to the utilisation of alternative sources of proteins, fibres and oils/fats, due to the increasing world population…

Expected Impact: The action under this topic is expected to achieve the following impacts: Accelerate EU access to more cost-effective interventions in an increasingly ageing population by identifying personalised treatment approaches for elderly-onset immune diseases. Decrease disease risk later in life by defining specific prevention strategies based on ageing biomarkers and risk factors. Halt age-associated disease exacerbation by the identification of predictive and digital biomarkers that can stratify patients for early intervention. Improve quality of life for healthy individuals and patients by preventing further health decline, avoiding escalating care costs, and properly stratifying individuals earlier in the diagnostic pathway. Accelerate adoption of innovative diagnostic, preventative, and therapeutic strategies, strengthening the EU’s position as a healthcare innovator. Evaluate digital biomarker as potential regulatory endpoints in the ultimate goal to develop medicines for ‘healthy ageing’. Integrate fragmented research efforts by bringing together health industry sectors and stakeholders to develop clinical and multi-omics data integration capabilities. Enable new…

Expected Impact: The action under this topic is expected to achieve the following impacts and contribute to the following EU policies/initiatives: deliver innovative, early technology solutions that contribute to addressing strategic unmet public health needs across multiple therapy areas to improve prevention, early diagnosis, and treatment; leverage the unique network and scale of IHI JU members to create a pipeline to support innovative startups in the health industry, fully integrated into European initiatives in support of start-ups and entrepreneurship; drive early cross-sector health R&D and innovation to strengthen the European healthcare industry’s global competitiveness, contributing to the EU Industrial Strategy and Pharmaceutical Strategy objectives; create a sustainable network of European healthcare incubators to guide and support highly talented and innovative early-stage companies; harness digital health and data-sharing technologies (e.g., AI and big data) to enable interoperable health solutions, contributing to the European Health Data Space (EHDS) and improved evidence based care;- the action should generate a portfolio of early‑stage companies that have…